Company
Portfolio Data
Back to Company SearchROBOLIGENT, INC.
UEI: L536MMYVL595
Number of Employees: 4
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 2017
2
Phase I Awards
2
Phase II Awards
100%
Conversion Rate
$334,965
Phase I Dollars
$2,549,035
Phase II Dollars
$2,884,000
Total Awarded
Awards
Robotic-assisted and user specific rehab technology to get patients back to their best life
Amount: $109,965 Topic: AFX23E-TPCSO1
Roboligent presents the Optimo Robot, a groundbreaking innovation in automated physical therapy for neuromuscular limb conditions. Optimo offers a cost-effective solution that surpasses the capabilities of multiple commercial products, enhancing patient outcomes, ensuring compliance, and minimizing therapy costs. Optimo provides a human-like and secure interaction with patients while delivering highly effective interventions. It replicates the range and forces applied by human therapists, optimizing the chances of successful recovery. This versatile robot accommodates exercises for arms, knees, and legs in various positions, catering to a diverse range of patients and facilitating extended, unsupervised therapy sessions. What sets Optimo apart is its patented, hyper-sensitive, force-controlled robotic system, operating within a full 3D motion space. It excels in supporting upper and lower limb exercises across different positions, offering interactive, natural movements. Optimo also tracks patients' range of motion and strength, enabling personalized progress trackingŚa feature lacking in many alternatives. Its adaptable assistance caters to varying severity levels, alleviating the burden on therapists, particularly during intensive gait training for stroke patients. Optimo's distinctive incorporation of impedance and force-based gait training holds the potential to redefine rehabilitation, delivering personalized, engaging, and highly effective outcomes, marking a significant advancement in neuromuscular therapy.
Tagged as:
STTR
Phase I
2024
DOW
USAF
Advanced Robotic-Assisted and Customized Rehabilitation Technology for Improving Recovery from Musculoskeletal and Stroke Conditions
Amount: $1,799,035 Topic: AFX23E-TPCSO1
Military personnel are frequently subjected to intense physical demands in both training and operational environments, resulting in a heightened risk of musculoskeletal injuries (MSIs). MSIs affect approximately 800,000 military service members annually, leading to 2.2 million medical visits, 25 million lost duty days, and healthcare costs totaling around $3.7 billion. Additionally, the prevalence of stroke among U.S. veterans is higher due to service-related risk factors such as combat exposure. The high incidence of MSIs and strokes in the military necessitates specialized resources to treat these conditions effectively.Robotic-assisted therapy devices can significantly reduce care costs and enhance recovery outcomes for these patients. Roboligent proposes to advance the development and demonstration of their Optimo rehabilitation robotic system to meet the Department of the Air Force's (DAF) demand for an efficient physical therapy robot. By providing automated, high-intensity, and evidence-based physical therapy for patients with neuromuscular impairments, Optimo can contribute to the core competency of "organizing, training, and equipping the Air Force."In this Phase II effort, Roboligent is partnering with the University of Texas at Austin as the Research Institution, aiming to adapt Optimo for a variety of military use cases. The focus is on customizing the user interface for military-specific rehabilitation protocols, enabling decentralized treatment, and ensuring compliance with military standards for security and patient data privacy. The project will involve collaboration with civil institutions to conduct multicenter trials, demonstrating the usability and safety of Optimo across different military deployment scenarios.
Tagged as:
STTR
Phase II
2024
DOW
USAF
SBIR Phase II: Force And Impedance-Based Exoskeleton Robots For Seamless Assistance And Neurologically Sound Rehabilitation
Amount: $750,000 Topic: EW
The broader societal impact/commercial potential of this project centers on improving rehabilitation outcomes for individuals suffering from motor dysfunction due to stroke, spinal cord injury, and other conditions. In the US alone, there are 600,000 new stroke patients each year who rely on conventional one-on-one therapies for recovery. Due to cost and labor limitations they do not receive consistent, frequent, and intensive training needed for full recovery and optimal quality of life. As a result, stroke care guidelines recommend robotic rehabilitation in all care settings. Providing robotic rehabilitation using the proposed exoskeleton robots is a compelling solution for hospitals, rehabilitation centers, and senior living communities. In addition to providing frequent and intensive therapy, the devices can accurately measure patient progress and performance for personalized care. The exoskeletons are also a powerful research tool into effective rehabilitation methods and have the potential to transform the manufacturing sector by providing a solution for industrial processes that are too complex for full automation and too physically demanding for humans. The proposed exoskeleton devices reduce the risk of injury from accidents and overexertion for individuals performing repetitive, high-stress tasks. Additional results include increased productivity and decreased absenteeism and turn-over. This Small Business Innovation Research (SBIR) Phase II project advances the development of exoskeleton robots targeted at rehabilitation. A substantial portion of the US population requires intensive rehabilitation services for neuromuscular impairment. Robotic rehabilitation has attracted attention due to the potential for better patient outcomes. Current robotic solutions lack the anatomical mobility and compliant dynamic behavior to produce neurologically-sound therapeutic behaviors. The proposed project addresses these deficits and will result in exoskeleton robots capable of essential advanced rehabilitation behaviors. During the Phase I project, a high-performance, force-controlled actuator was developed and will be the core component enabling the desired behavior. In this project, the physical structures and control algorithms of the exoskeletons will be designed and built with a focus on dynamic transparency and kinematic compatibility with the human body to capitalize on the capabilities of the actuator. Additionally, the control software will use feedback loops and a visually interactive environment with performance metrics to keep patients engaged. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Tagged as:
SBIR
Phase II
2019
NSF
SBIR Phase I: A High-Force-Fidelity and Compact Actuator for an Upper-Body Exoskeletal Rehabilitation Robot
Amount: $225,000 Topic: EW
The broader impact/commercial potential of this project is significant. The compact and torque-controllable proposed actuator will prompt the development of a highly-potential upper-body exoskeletal rehabilitation robot that support a wide range of motion with an anatomical mobility and impedance-based dynamic behaviors. The high-performed exoskeleton will allow to implement contemporary therapeutic trainings based on neurological motor learning principles. This would enhance the efficacy of robotic rehabilitation leading to better recovery after neuromuscular injuries. Therefore, rehabilitation robots powered by the proposed actuator will be better accepted to physical rehabilitation market and bring a significant commercial impact. Ultimately, this project will contribute to reduction of socio-economic costs caused by neuromuscular impairments. Also, exoskeletons powered by the proposed actuator would contribute to better understanding of neurobehavioral principle of human body by serving as an experimental tool that creates force-based human-robot interactions with anatomical movements. This Small Business Innovation Research (SBIR) Phase I project will focus on developing a compact rotary-type series elastic actuators (SEAs) for upper-body exoskeleton application. A substantial portion of the US population suffers from neuromuscular impairments, requiring intensive rehabilitation services. Robotic rehabilitation has been attracting attention from many sectors because of the potential for better rehabilitation outcome. However, the lack of anatomical shoulder mobility and compliant dynamic control in existing upper-body exoskeletons limits the capability to produce neurologically-based therapeutic behaviors. The proposed SEAs will help to overcome the limitation by enabling exoskeletons to have force and impedance-based behaviors for advanced rehabilitation protocols. Its compact form factor will benefit the linkage design of exoskeletons for a wide range of motion and anatomical mobility. Also, the SEAs with the tight configuration and high torque/power capacity will provide a high flexibility in a variety of robot designs contributing to advances of general robotic technology.
Tagged as:
SBIR
Phase I
2017
NSF